3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) appointed Dr. Kevin Little, a leading biomedical scientist and corporate executive, as its new chief scientific officer, effective immediately.
In this role, Dr. Little will oversee the design, development and implementation of the company’s clinical programs.
Prior to his position at 3DS, Dr. Little worked as an independent consultant, offering strategic advisory services to help facilitate new life sciences collaborations and research-related systems for public and private sector clients, including Thomson Reuters, Illumina, Janssen, McGill University and the Global Alliance for Genomics and Health.
He also has spent several years leading the New Zealand government’s economic development efforts to build strategic investment relationships across the biotechnology industry sector.
In a statement, Jason Flowerday, CEO of 3D Signatures, said Dr. Little has an outstanding track record in helping life sciences companies grow, and “we look forward to working with him to bring 3DS’ transformational technology to market.”
Dr. Little added that 3DS’ platform is fundamentally different from conventional diagnostic methods, and represents an entirely new diagnostic paradigm.
“This disruptive technology has the potential to dramatically improve patient outcomes, something I’m very passionate about, while, at the same time, reducing costs and improving resource use across the healthcare system,” he said.